← Back to Search

CDK4/6 Inhibitor

Pembrolizumab for Gastroesophageal Cancer

Phase 2
Waitlist Available
Led By Nataliya Uboha, MD, PhD
Research Sponsored by Nataliya Uboha
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from c1d1 until death or up to a maximum of 6 months
Awards & highlights

Study Summary

This trial will test a new combination therapy for advanced gastric cancer.

Eligible Conditions
  • Gastroesophageal Cancer
  • Adenocarcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from c1d1 until death or up to a maximum of 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from c1d1 until death or up to a maximum of 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-Free Survival(PFS)
Secondary outcome measures
Disease Control Rate
Number of Participants With Specified Safety and Tolerability of Abemaciclib in Combination With Pembrolizumab
Objective Response Rate
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Abemaciclib and PembrolizumabExperimental Treatment2 Interventions
Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010
Abemaciclib
2019
Completed Phase 2
~1710

Find a Location

Who is running the clinical trial?

Nataliya UbohaLead Sponsor
1 Previous Clinical Trials
39 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,613 Previous Clinical Trials
3,200,926 Total Patients Enrolled
Nataliya Uboha, MD, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison
2 Previous Clinical Trials
91 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still enrolling patients for this treatment program?

"No, this particular clinical trial is not actively recruiting patients at the moment. However, there are 1885 other active studies that might be of interest. This particular study was first posted on 8/26/2019 and had its last update on 2/16/2022."

Answered by AI

Abemaciclib is most commonly used to target which forms of cancer?

"Abemaciclib is frequently used to treat cancer, though it can also be employed to help patients with unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."

Answered by AI

How many human participants are included in this experiment?

"As of the most recent update on February 16th, 2022, this trial is not presently looking for patients. This study was originally posted on 8/26/2019. If you are searching for other studies, there are presently 796 trials actively enrolling patients with adenocarcinoma and 1089 studies for Abemaciclib actively searching for patients."

Answered by AI

Is this clinical trial common in Canadian hospitals?

"There are several clinical sites participating in this research, including the University of Wisconsin in Madison, Rutgers Cancer Institute of New jersey in New Brunswick, and Indiana University Melvin and Bren Simon Cancer Center in Indianapolis."

Answered by AI

Has the Food and Drug Administration cleared Abemaciclib for use?

"Abemaciclib has received a score of 2 from our team at Power. This is due to the fact that, while Phase 2 trials have some data supporting safety, there is currently no evidence that this medication is effective."

Answered by AI

Has Abemaciclib been used in other scientific research studies?

"Abemaciclib was originally studied in 2009. For more information about the clinical trial sites for this drug, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday through Friday from 9 a.m. to 5 p.m. Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. There have been 278 completed studies and there are currently 1089 live studies underway, many of which are being conducted in Madison, Wisconsin."

Answered by AI

What is unique about this particular clinical trial?

"Abemaciclib is being trialed in 1089 active studies, located in 3261 cities and 64 countries. The first trial began in 2009, and it completed Phase 1 drug approval with the support of Eli Lilly and Company. 220 patients were enrolled in the initial study. In the years since 2009, an additional 278 studies have been conducted."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Nataliya Uboha 2019. "Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03997448.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top